{
 "brief_date": "2026-10-26",
 "generated_at": "2026-10-26T07:50:01.132083+08:00",
 "window": {
  "from": "2026-10-23",
  "to": "2026-10-26"
 },
 "instructions": "这是小动物医学简报的原始素材包。只使用本文件条目生成简报：临床研究/指南与监管写中文要点、英文要点、来源与日期、证据级别、链接；疾病预警只写中文翻译+原文链接；不要编造，未提供的结论不要写。",
 "counts": {
  "clinical_research": 6,
  "guidelines_regulation": 7,
  "disease_alerts": 6
 },
 "categories": {
  "clinical_research": [
   {
    "id": "pmid:42915224",
    "source": "PubMed",
    "journal": "Journal of the American Veterinary Medical Association",
    "date": "2026-10-23",
    "title": "Systematic review supports the idea that no alternative test presently replaces elimination diet test and oral food challenge to diagnose canine adverse food reactions.",
    "abstract": "Adverse food reactions in dogs are clinically heterogeneous and overlap with canine atopic dermatitis, and diagnosis still relies on an elimination diet test followed by oral food challenge (EDT+OFC). Numerous allergen-specific tests have been proposed, but their diagnostic value remains controversial. Our objective was to identify, synthesize, and critically evaluate the diagnostic tests used or investigated for canine food allergy, with emphasis on their clinical validity, applicability, and agreement with the EDT+OFC reference standard. In accordance with PRISMA (ie, Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 guidelines, Scopus and PubMed were searched without publication-year restrictions, and records were independently screened in duplicate at the title, abstract, and full-text stages. A meta-analysis was not feasible owing to heterogeneity. Fifty-nine studies (1986 to 2025) from 16 countries were included and grouped into elimination/provocation diets and serological, cutaneous, cellular, and molecular tests. The most consistently validated approach remained EDT+OFC. Serological IgG/IgE (and salivary) tests were poorly correlated with clinical outcome; the standardized patch test showed the best cutaneous performance (high negative predictive value), cellular tests (lymphocyte proliferation) showed the closest concordance with the OFC, and molecular/proteomic methods advanced allergen characterization and the understanding of cross-reactivity. No alternative test reliably replaces EDT+OFC. Although patch testing may seem beneficial, its p",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42915224/",
    "doi": "10.2460/javma.26.06.0456",
    "pmid": "42915224",
    "authors": [
     "Roger Morales-Romero",
     "María S Gonzalez-Dominguez",
     "Wendie Roldán-Villalobos"
    ],
    "collected_by": "pubmed_core",
    "priority": 104
   },
   {
    "id": "pmid:42915069",
    "source": "PubMed",
    "journal": "Journal of the American Veterinary Medical Association",
    "date": "2026-10-23",
    "title": "Diagnosis of exocrine pancreatic insufficiency in dogs requires use of a newly adjusted reference range and diagnostic cutoff for measurement of trypsin-like immunoreactivity.",
    "abstract": "To adjust the reference interval (RI) for a commercially available canine trypsin-like immunoreactivity (cTLI) assay and the cutoff value for the diagnosis of exocrine pancreatic insufficiency (EPI). Lower limit of the RI was calculated based on the fifth percentile of cTLI concentrations in 102 clinically healthy dogs. Questionnaires were sent to clinicians for cases with serum cTLI concentrations ≤ 10 µg/L. Five board-certified small animal internists blinded to serum cTLI concentration individually reviewed questionnaire responses to clinically classify each dog. Dogs were classified as \"EPI\" or \"not EPI\" based on the consensus when ≥ 4 internists assigned the same classification. The cutoff was determined by maximizing the weighted Youden index (1.34 × sensitivity + 0.67 × specificity - 1). Sensitivity was prioritized, as false negatives were considered more deleterious than false positives. The calculated lower RI limit was ≥ 11.8 µg/L. Forty-seven dogs each were classified as EPI and not EPI. The median (range) serum cTLI concentrations were 1.5 µg/L (0.9 to 7.2) for the EPI dogs and 8.3 µg/L (2.2 to 10.0) for the not EPI dogs. The optimal diagnostic cutoff was 5.5 µg/L, with a sensitivity of 95.7% and specificity of 83.0%. Use of the updated RI (≥ 11.8 µg/L) and diagnostic cutoff value for EPI (5.5 µg/L) should reduce false-negative results when using this commercial assay. There has been an upward shift in serum cTLI measurements with this commercial assay, consistent with clinical observations.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42915069/",
    "doi": "10.2460/javma.26.05.0350",
    "pmid": "42915069",
    "authors": [
     "Wei-Hsiu Chuang",
     "Yu-An Wu",
     "Jonathan A Lidbury"
    ],
    "collected_by": "pubmed_core",
    "priority": 104
   },
   {
    "id": "pmid:42915569",
    "source": "PubMed",
    "journal": "American journal of veterinary research",
    "date": "2026-10-23",
    "title": "Tablet crushing, but not splitting, alters the pharmacokinetics of extended-release levetiracetam in dogs.",
    "abstract": "To compare the pharmacokinetics of intact, split, and crushed levetiracetam (LEV) extended-release (LEV-XR) tablets in dogs. We hypothesized that splitting produces a pharmacokinetic profile similar to intact tablets, whereas crushing results in earlier and higher maximum concentrations. Healthy research dogs were administered 500 mg LEV-XR orally as intact, split, or crushed tablets in a randomized crossover design. Plasma LEV concentrations were measured over 12 hours by high-pressure liquid chromatography. Pharmacokinetic parameters were estimated using noncompartmental analysis and supplementary compartmental analysis and compared using linear mixed-effects models. The study utilized 7 Beagles. Compared with intact tablets, crushed tablets resulted in higher maximum concentration (Cmax) values (61.5 vs 46.0 µg/mL; geometric mean ratio, 1.34; 95% CI, 1.08 to 1.65) and lower 8- to 12-hour exposure (30.0 vs 49.8 µg·h/mL; geometric mean ratio, 0.60; 95% CI, 0.47 to 0.77). Duration above the targeted concentration of 10 µg/mL was longer with intact than crushed tablets (10.9 vs 8.5 hours; mean difference, 2.37 hours; 95% CI, 1.02 to 3.72). Exploratory compartmental analysis estimated an earlier time to maximum concentration (Tmax) for crushed compared with intact tablets. No statistically significant differences were observed between intact and split tablets. Splitting LEV-XR tablets did not significantly alter the evaluated pharmacokinetic parameters, whereas crushing resulted in a higher Cmax, an earlier model-estimated Tmax, and reduced late exposure. Splitting LEV-XR tab",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42915569/",
    "doi": "10.2460/ajvr.26.08.0360",
    "pmid": "42915569",
    "authors": [
     "Alejandra Mondino",
     "Julie A Nettifee",
     "Katherine E Simon"
    ],
    "collected_by": "pubmed_core",
    "priority": 74
   },
   {
    "id": "pmid:42925095",
    "source": "PubMed",
    "journal": "Veterinary dermatology",
    "date": "2026-10-23",
    "title": "Development and Validation of a New Online Tool for Monitoring Clinical Signs of Canine Atopic Dermatitis.",
    "abstract": "The aim of the study was to develop a simple, reliable and validated patient-reported outcome tool for use in monitoring the severity of clinical signs in dogs with confirmed or suspected atopic allergies and recurrent otitis externa. The tool is called the Dog-Orientated Severity of Atopy Scale (DOSAS). The human Patient-Oriented Eczema Measure (POEM) was adapted for relevance to the owner-observable clinical signs of canine atopic dermatitis (cAD). Refinements were made via consultation with dog owners and veterinary surgeons to ensure applicability and ease of use. Relevant features of reliability (including internal consistency, intrarater reliability and test-retest reliability) were evaluated. The tool was then tested by owners and clinicians for performance against established clinical sign assessment methods. The DOSAS was shown to be both reliable and valid with psychometric properties above acceptable guidelines for the development of such tools. Guidelines are presented for score creation and stratification of the score to enable interpretation. When compared to how severity assessment scores from Canine Atopic Dermatitis Extent and Severity Index, 4th iteration (CADESI-04) and pruritus Visual Assessment Scale (PVAS) responded to change, the DOSAS performed particularly strongly, although it performed less well when compared to the 0-3 Otitis Index Score (OTIS-3). The DOSAS is presented as a supplementary tool for use in veterinary practice and clinical research programmes alongside existing clinical measurements such as CADESI-04, providing a focus on the diseas",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42925095/",
    "doi": "10.1111/vde.70133",
    "pmid": "42925095",
    "authors": [
     "Naomi Harvey",
     "Adrian Watson",
     "Jeremy Laxalde"
    ],
    "collected_by": "pubmed_core",
    "priority": 69
   },
   {
    "id": "pmid:42918624",
    "source": "PubMed",
    "journal": "Veterinary and comparative oncology",
    "date": "2026-10-23",
    "title": "Retrospective Application of the Current International Myeloma Working Group Disease Definitions in 20 Cats With Immunoglobulin Secreting Neoplasms.",
    "abstract": "Studies describing feline myeloma related diseases (MRD) are limited and reported prognostic indicators are inconsistent. Cats more commonly exhibit visceral plasma cell tumours (PCTs) than marrow-predominant disease, suggesting that diagnostic approaches adapted from the International Myeloma Working Group (IMWG) criteria, incorporating extramedullary involvement and myeloma defining events (MDEs), may better capture clinically relevant disease. We sought to evaluate cats with serum protein electrophoresis (SPE) and immunofixation (IF) confirmed M-proteins using IMWG-adapted criteria, determine how often cases satisfy IMWG-adapted versus classic multiple myeloma (MM) definitions, compare outcomes, characterize clinical and laboratory findings and assess prognostic indicators. A retrospective cohort of 20 cats with SPE/IF-confirmed M-proteins and clinical data was included in the study applying IMWG-adapted and classic MM criteria using available clinical records, laboratory data and cytologic or histologic findings. Survival was evaluated using the log-rank test. 14/20 cats met IMWG-adapted MM criteria, whereas 7 cats met classic criteria. Median survival time did not differ between classic MM (226.5 days) and IMWG-reclassified MM (141 days; p = 0.99). Visceral organ involvement was common; splenic PCTs occurred in 71.4% (10/14) and hepatic PCTs in 87.5% (7/8) of sampled organs. Lytic bone lesions were infrequent (3/14). IgG M-proteins predominated (71.4%). No clinicopathologic variable was significantly associated with survival. IMWG-adapted criteria reclassified MM witho",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42918624/",
    "doi": "10.1111/vco.70123",
    "pmid": "42918624",
    "authors": [
     "Christina M Jeffries",
     "R Adam Harris",
     "Kathryn Vickery"
    ],
    "collected_by": "pubmed_core",
    "priority": 69
   },
   {
    "id": "pmid:42924521",
    "source": "PubMed",
    "journal": "Microbial drug resistance (Larchmont, N.Y.)",
    "date": "2026-10-23",
    "title": "Co-occurrence of blaNDM-5 and mcr-1 on Two Distinct, Independently Transferable Plasmids in Commensal Escherichia coli ST156 from a Healthy Companion Dog.",
    "abstract": "The emergence of carbapenem- and colistin-resistant Enterobacterales mediated by transmissible plasmids poses a critical One Health threat by compromising the efficacy of last-resort antimicrobials. We characterized a commensal Escherichia coli ST156 isolate recovered from a clinically healthy companion dog in South Korea that carried blaNDM-5 and mcr-1 on distinct plasmids. Antimicrobial susceptibility testing revealed a multidrug-resistant phenotype, including resistance to carbapenems (imipenem MIC, ≥8 μg/mL) and colistin (MIC, 8 μg/mL). Hybrid long- and short-read genome assembly localized blaNDM-5 to an IncX3 plasmid and mcr-1 to an IncX4 plasmid. Broth-mating assays showed that each plasmid was independently transferable under the corresponding single-antimicrobial selection. Among 30 transconjugant colonies screened under each selection, both resistance determinants were detected in five colistin-selected and two meropenem-selected colonies, indicating co-detection of both resistance determinants in a minority of the screened colonies. Comparative genomic analysis showed that the IncX4-mcr-1 plasmid shared a highly conserved backbone with globally distributed IncX4 plasmids from diverse sources. These findings demonstrate asymptomatic carriage of independently transferable carbapenem- and colistin-resistance plasmids in a companion animal and support the inclusion of companion animals in integrated antimicrobial resistance surveillance.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42924521/",
    "doi": "10.1177/10766294261500214",
    "pmid": "42924521",
    "authors": [
     "Jae Young Oh",
     "Lan Hee Kim",
     "Sungpyo Kim"
    ],
    "collected_by": "pubmed_alerts",
    "priority": 54
   }
  ],
  "guidelines_regulation": [
   {
    "id": "fr:2026-21718",
    "source": "Federal Register / FDA",
    "journal": "Federal Register (Notice)",
    "date": "2026-10-26",
    "title": "Issuance of Priority Review Voucher; Rare Pediatric Disease Product; ISEMBYLD (apitegromab-mstn)",
    "abstract": "The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that ISEMBYLD (apitegromab-mstn), approved September 11, 2026, manufactured by Scholar Rock, Inc., meets the criteria for a priority review voucher.",
    "url": "https://www.federalregister.gov/documents/2026/10/26/2026-21718/issuance-of-priority-review-voucher-rare-pediatric-disease-product-isembyld-apitegromab-mstn",
    "doi": null,
    "pmid": null,
    "document_number": "2026-21718",
    "collected_by": "federal_register",
    "priority": 0,
    "category_hint": "regulation"
   },
   {
    "id": "pmid:42927477",
    "source": "PubMed",
    "journal": "Veterinary pathology",
    "date": "2026-10-25",
    "title": "A large-scale consensus study of a diagnostic algorithm for canine and feline mammary tumor histopathology: An attempt to improve inter-observer agreement.",
    "abstract": "Histological classification of mammary proliferative lesions in dogs and cats is essential for prognostic and predictive studies, as well as for comparative oncology; however, standardization of diagnoses is highly affected by substantial interobserver variability. In this study, a structured diagnostic algorithm based on the Davis-Thompson Foundation classification was assessed for the ability to improve interobserver agreement in the morphological diagnoses of mammary gland lesions in dogs and cats. Consensus diagnoses of 114 selected mammary lesions (91 canine, 23 feline) made by 16 veterinary pathologists with mammary tumor expertise were used as the gold standard, and 79 veterinary pathologists from 21 countries evaluated digitized whole slides in 2 rounds: a first reading without the algorithm and a second reading with the algorithm. Interobserver concordance was measured using unweighted kappa statistics for lesion category (hyperplastic/dysplastic, benign, malignant) and histological subtype. Across all lesions, agreement was higher for lesion category than for histological subtype. A slight improvement in concordance was observed when applying the algorithm, both for category (k = 0.72, before, and k = 0.73, after) and histotype classifications (k = 0.40, before to k = 0.42, after). Also, by using the algorithm, 73/79 raters (92%) modified at least 1 diagnosis and, among these, approximately two-thirds reached agreement with the gold standard in at least 1 case. Considering histotypes, malignant tumors with mixed epithelial and myoepithelial components showed persi",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42927477/",
    "doi": "10.1177/03009858261472763",
    "pmid": "42927477",
    "authors": [
     "Cristiano Cocumelli",
     "Maria-Ines Crescio",
     "Jessica M Abbate"
    ],
    "collected_by": "pubmed_guidelines",
    "priority": 58
   },
   {
    "id": "fr:2026-21714",
    "source": "Federal Register / FDA",
    "journal": "Federal Register (Notice)",
    "date": "2026-10-23",
    "title": "Agency Information Collection Activities; Proposed Collection; Comment Request; Export Certificates for FDA Regulated Products",
    "abstract": "The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on export certificates for FDA regulated products.",
    "url": "https://www.federalregister.gov/documents/2026/10/23/2026-21714/agency-information-collection-activities-proposed-collection-comment-request-export-certificates-for",
    "doi": null,
    "pmid": null,
    "document_number": "2026-21714",
    "collected_by": "federal_register",
    "priority": 0,
    "category_hint": "regulation"
   },
   {
    "id": "fr:2026-21516",
    "source": "Federal Register / FDA",
    "journal": "Federal Register (Notice)",
    "date": "2026-10-21",
    "title": "Regulatory Considerations for Prescription Drug Use-Related Software; Guidance for Industry; Availability",
    "abstract": "The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry titled \"Regulatory Considerations for Prescription Drug Use-Related Software.\" This final guidance describes FDA's application of its drug labeling authorities to certain software outputs that are disseminated by or on behalf of a drug sponsor for use with a prescription drug product or a prescription drug-led, drug-device combination product that is assigned to the Center for Drug Evaluation and Research or the Center for Biologics Evaluation and Research as the lead center. This guidance finalizes the draft guidance of the same title issued on September 19, 2023.",
    "url": "https://www.federalregister.gov/documents/2026/10/21/2026-21516/regulatory-considerations-for-prescription-drug-use-related-software-guidance-for-industry",
    "doi": null,
    "pmid": null,
    "document_number": "2026-21516",
    "collected_by": "federal_register",
    "priority": 0,
    "category_hint": "regulation"
   },
   {
    "id": "fr:2026-21453",
    "source": "Federal Register / FDA",
    "journal": "Federal Register (Notice)",
    "date": "2026-10-20",
    "title": "New Dietary Ingredient (NDI) Notifications and Related Issues; Identity and Safety Information About the NDI: Guidance for Industry; Availability",
    "abstract": "The Food and Drug Administration (FDA or we) is announcing the availability of a final guidance for industry entitled \"New Dietary Ingredient (NDI) Notifications and Related Issues; Identity and Safety Information About the NDI: Guidance for Industry.\" The guidance focuses on frequently asked questions about the new dietary ingredient notification (NDIN) submissions. This guidance is intended to help provide recommendations to manufacturers and distributors of NDIs and dietary supplements containing an NDI regarding the identity and safety information that should be included in an NDIN.",
    "url": "https://www.federalregister.gov/documents/2026/10/20/2026-21453/new-dietary-ingredient-ndi-notifications-and-related-issues-identity-and-safety-information-about",
    "doi": null,
    "pmid": null,
    "document_number": "2026-21453",
    "collected_by": "federal_register",
    "priority": 0,
    "category_hint": "regulation"
   },
   {
    "id": "feed:WSAVA:https://wsava.org/updates/advancing-dental-care-worldwide-our-updated-global-dental-guidelines-are-here/",
    "source": "WSAVA RSS",
    "journal": "WSAVA",
    "date": "2026-09-24",
    "title": "Advancing Dental Care Worldwide: Our Updated Global Dental Guidelines Are Here",
    "abstract": "Our updated 2026 Global Dental Guidelines are now available, providing veterinary professionals worldwide with practical, evidence-based guidance to support the prevention, diagnosis and treatment of oral and dental disease in companion animals.",
    "url": "https://wsava.org/updates/advancing-dental-care-worldwide-our-updated-global-dental-guidelines-are-here/",
    "doi": null,
    "pmid": null,
    "category_hint": "guidelines",
    "collected_by": "feed_wsava",
    "priority": 0
   },
   {
    "id": "feed:WSAVA:https://wsava.org/updates/update-on-the-working-group-following-erratum-published-in-march-2025/",
    "source": "WSAVA RSS",
    "journal": "WSAVA",
    "date": "2026-08-29",
    "title": "Update on the Working Group following Erratum Published in March 2025",
    "abstract": "WSAVA has published an update on the Multidisciplinary Reproduction Control Working Group following the Erratum published in March 2025.",
    "url": "https://wsava.org/updates/update-on-the-working-group-following-erratum-published-in-march-2025/",
    "doi": null,
    "pmid": null,
    "category_hint": "guidelines",
    "collected_by": "feed_wsava",
    "priority": 0
   }
  ],
  "disease_alerts": [
   {
    "id": "dvm360:https://www.dvm360.com/view/weekly-vet-report-thousands-of-veterinary-drugs-recalled-fda-drug-approval-more",
    "source": "dvm360",
    "journal": "dvm360",
    "date": "2026-10-24",
    "title": "Weekly Vet Report: Thousands of veterinary drugs recalled, FDA drug approval + more",
    "abstract": "A nationwide recall of thousands of compounded veterinary medication listings, the first New World screwworm detection in US wildlife since the parasite’s return, and a new FDA-approved antibiotic formulation for certain skin infections in dogs.",
    "url": "https://www.dvm360.com/view/weekly-vet-report-thousands-of-veterinary-drugs-recalled-fda-drug-approval-more",
    "doi": null,
    "pmid": null,
    "category_hint": "media_alert",
    "collected_by": "dvm360",
    "priority": 0
   },
   {
    "id": "gnews:https://news.google.com/rss/articles/CBMi8wFBVV95cUxOUVgwVmtLQXZFTTlLeEZONmpjVmhCSVZqNWNNV0ltRHhFYVVzSmNoSTlOYURXbTl4VUpKeWxtYWhSSzY4XzRKeFBxX3VldFctZ0NuUWllUjBYbWstb1ViY2tlZjFiWEJ",
    "source": "Google News",
    "journal": "Google News: new world screwworm dog",
    "date": "2026-10-23",
    "title": "How to protect your pets from the New World screwworm: Complete guide for dog and cat owners after Texas outbreak - Clarin.com",
    "abstract": "How to protect your pets from the New World screwworm: Complete guide for dog and cat owners after Texas outbreak  Clarin.com",
    "url": "https://news.google.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?oc=5",
    "doi": null,
    "pmid": null,
    "category_hint": "media_alert",
    "collected_by": "gnews",
    "priority": 0
   },
   {
    "id": "gnews:https://news.google.com/rss/articles/CBMihgFBVV95cUxNYjdFSjdJbEx5MUF6ZUtfd2hzcTYwTkZCdU5QVlJzQ25lWTd1QnZXa3VaRzQyU014cHJIXzlCSjVwUEZ2cW5lOWRuN0lOdUkyWjNKckNrNkQ5XzY3S2QzS09QX0F6R29",
    "source": "Google News",
    "journal": "Google News: new world screwworm dog",
    "date": "2026-10-23",
    "title": "Screwworm in Texas: How to keep pets safe - FOX 4 News Dallas-Fort Worth",
    "abstract": "Screwworm in Texas: How to keep pets safe  FOX 4 News Dallas-Fort Worth",
    "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNYjdFSjdJbEx5MUF6ZUtfd2hzcTYwTkZCdU5QVlJzQ25lWTd1QnZXa3VaRzQyU014cHJIXzlCSjVwUEZ2cW5lOWRuN0lOdUkyWjNKckNrNkQ5XzY3S2QzS09QX0F6R29RMkhPaVNtcUg4RFBKX01tTHlmLTBHTk1iM19LRl9kQdIBiwFBVV95cUxNS1NVNmdmeEEyaFROYzk5UGhGQThsVThra1BnWkoxS3Y1UHJqSW94dWE1NnpEaDVJTlo1bTVvRE9ZanZMNlhEa3RNM29LQldLZUVnbUNPdEdjLVREM01PeVRvdFRoOUlVaWUwcDEwbnVIY2tIdThPcW10ZVFYWkJqOTFKVEZTUl9CM3dz?oc=5",
    "doi": null,
    "pmid": null,
    "category_hint": "media_alert",
    "collected_by": "gnews",
    "priority": 0
   },
   {
    "id": "gnews:https://news.google.com/rss/articles/CBMitAFBVV95cUxOS1dsaW9HbWhiOFFjcDlUdFNsTUFjYk1qWDV6RWpVZGJaamU3cElGbERJanVCNUhrZGJtY2c4MFI3Wm53a3Q5TjYxYzI5OTRjZ2VmZjE0YXRfTGFCakhUNjZGWG1Hc3R",
    "source": "Google News",
    "journal": "Google News: dog parvovirus outbreak",
    "date": "2026-10-22",
    "title": "Vet urges more pet owners to get dogs vaccinated amid virus outbreak - Kent Online",
    "abstract": "Vet urges more pet owners to get dogs vaccinated amid virus outbreak  Kent Online",
    "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOS1dsaW9HbWhiOFFjcDlUdFNsTUFjYk1qWDV6RWpVZGJaamU3cElGbERJanVCNUhrZGJtY2c4MFI3Wm53a3Q5TjYxYzI5OTRjZ2VmZjE0YXRfTGFCakhUNjZGWG1Hc3RTc3AzX0lPYmpSNDNXbEFOMGFNRUtjUlJCNHFNeHV2NUFpTzZUSXBZQk9zMm5YeGIzenRnM3FxR0hid1lvd3lCSjdVRkFZX2hSUTBPSlk?oc=5",
    "doi": null,
    "pmid": null,
    "category_hint": "media_alert",
    "collected_by": "gnews",
    "priority": 0
   },
   {
    "id": "dvm360:https://www.dvm360.com/view/higher-concentration-cefovecin-approved-by-fda-for-certain-skin-infections-in-dogs",
    "source": "dvm360",
    "journal": "dvm360",
    "date": "2026-10-21",
    "title": "Higher-concentration cefovecin approved by FDA for certain skin infections in dogs",
    "abstract": "A new version of an injectable antibiotic, first approved in 2008, is approved only for dogs, as 2 of its inactive ingredients may be toxic to cats.",
    "url": "https://www.dvm360.com/view/higher-concentration-cefovecin-approved-by-fda-for-certain-skin-infections-in-dogs",
    "doi": null,
    "pmid": null,
    "category_hint": "media_alert",
    "collected_by": "dvm360",
    "priority": 0
   },
   {
    "id": "dvm360:https://www.dvm360.com/view/dvm360-live-returns-with-a-doj-pet-food-lawsuit-screwworm-surveillance-and-more",
    "source": "dvm360",
    "journal": "dvm360",
    "date": "2026-10-16",
    "title": "dvm360 Live! returns with a DOJ pet food lawsuit, screwworm surveillance, and more",
    "abstract": "Adam Christman, DVM, MBA, returns as host for season 3, featuring a roundup of recent veterinary news and an appearance by guest Steve Mehler, DVM, DACVS.",
    "url": "https://www.dvm360.com/view/dvm360-live-returns-with-a-doj-pet-food-lawsuit-screwworm-surveillance-and-more",
    "doi": null,
    "pmid": null,
    "category_hint": "media_alert",
    "collected_by": "dvm360",
    "priority": 0
   }
  ]
 },
 "sources": {
  "pubmed_core": {
   "ok": true,
   "count": 12
  },
  "pubmed_alerts": {
   "ok": true,
   "count": 5
  },
  "pubmed_guidelines": {
   "ok": true,
   "count": 1
  },
  "federal_register": {
   "ok": true,
   "count": 4
  },
  "feed_WSAVA": {
   "ok": true,
   "count": 2
  },
  "dvm360": {
   "ok": true,
   "count": 3
  },
  "gnews:new world screwworm dog": {
   "ok": true,
   "count": 3
  },
  "gnews:H5N1 cat": {
   "ok": true,
   "count": 0
  },
  "gnews:dog parvovirus outbreak": {
   "ok": true,
   "count": 1
  },
  "gnews:canine distemper outbreak": {
   "ok": true,
   "count": 0
  },
  "gnews:cytauxzoonosis cat": {
   "ok": true,
   "count": 0
  },
  "gnews:screwworm New Mexico": {
   "ok": true,
   "count": 0
  }
 }
}